CDH1 and central nervous system cancer: Furthermore, in low-grade gliomas, including ODs, CDH1 is frequently altered by an alternative mechanism, i.e. hypermethylation of its promoter, resulting in down-regulated E-cadherin expression and worse outcome of patients [12].